Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 12/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13183607 | 0.79 | NOTUM (0.53) | RXRAGRIN1GRIN2B | |
| SCHEMBL13160180 | 0.79 | NOTUM (0.51) | KCNH2 | |
| SCHEMBL23008630 | 0.77 | CYP1B1 (0.37) | RXRAGRIN1GRIN2BEGLN2 | |
| SCHEMBL9729936 | 0.77 | FLT3 (0.46) | RXRAGRIN1GRIN2B | |
| SCHEMBL13119830 | 0.77 | P2RX7 (0.50) | — | |
| SCHEMBL19589440 | 0.75 | MAOA (0.50) | RXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL20046658 | 0.75 | RXRA (0.41) | RXRAGRIN1GRIN2BEGLN2KCNH2 | |
| SCHEMBL15044963 | 0.75 | NOTUM (0.60) | — | |
| SCHEMBL20437894 | 0.75 | NOTUM (0.60) | — | |
| SCHEMBL22185933 | 0.73 | NOTUM (0.55) | RXRAGRIN1GRIN2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | RXRA 3394/4885GRIN1 3154/4885GRIN2B 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.